Loading...
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
PURPOSE: Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (anti-PD-L1) as an early OS surrogate. METHODS: S...
Na minha lista:
| Udgivet i: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7857603/ https://ncbi.nlm.nih.gov/pubmed/33534859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0246486 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|